Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2001
09/07/2001CA2397657A1 Farnesyl protein transferase inhibitor combinations with platinum compounds
09/07/2001CA2397475A1 Farnesyl protein transferase inhibitor combinations with vinca alkaloids
09/07/2001CA2397448A1 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
09/07/2001CA2397446A1 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
09/07/2001CA2397425A1 Farnesyl protein transferase inhibitor combinations with taxane compounds
09/07/2001CA2397349A1 Farnesyl protein transferase inhibitor combinations with an her2 antibody
09/07/2001CA2397256A1 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
09/07/2001CA2397253A1 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
09/07/2001CA2397240A1 Farnesyl protein transferase inhibitor combinations with camptothecin compounds
09/07/2001CA2397165A1 Thienopyridine derivatives, their production and use
09/07/2001CA2396504A1 Inhibitors of hepatitis c virus ns3 protease
09/07/2001CA2374585A1 Antimicrobial sanitizing lotion with skin protection properties
09/07/2001CA2372185A1 Novel pharmaceutical or dietetic mushroom-based compositions
09/07/2001CA2339676A1 Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection
09/06/2001US20010020170 Spinal implants, insertion instruments, and methods of use
09/06/2001US20010020114 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives
09/06/2001US20010020097 Treatment of Alzheimer's disease
09/06/2001US20010020095 High affinity for D4 receptors; treatment of schizophrenia, other psychoses, anxiety disorders, depression, alcohol abuse, impulse control disorders, aggression
09/06/2001US20010020083 Sulfiding/nitrosylating cyclodextrins to form coating for medical devices (tubes, catheters)
09/06/2001US20010020043 Administering polyhydroxylated stilbene
09/06/2001US20010020042 Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
09/06/2001US20010020041 Improve viability of sperm; mixture containing antioxidant
09/06/2001US20010020040 Hyperforin derivatives, use thereof and formulations containing them
09/06/2001US20010020039 Controlled release formulation of divalproex sodium
09/06/2001US20010020038 Using 4-(((cyanoimino)-((1,2,2-trimethylpropyl)amino) methyl)amino)benzonitrile
09/06/2001US20010020036 Synergistic mixtures
09/06/2001US20010020034 Isothiazole derivatives useful as anticancer agents
09/06/2001US20010020032 Olanzapine
09/06/2001US20010020031 Compositions of optically pure (+) norcisapride
09/06/2001US20010020029 New multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H- indazole-3-carboxamide hydrochloride
09/06/2001US20010020028 Agents for treating neurodegenerative disorders
09/06/2001US20010020027 Using 1-(4-(1-(4-fluorophenyl)-1H-indole-3-yl)-1-butyl spiro(isobenzofuran-1(3H,4-piperidine)
09/06/2001US20010020025 Mixture of antiserotonine compound with laxative; therapy for constipation
09/06/2001US20010020024 Opioid analgesics
09/06/2001US20010020023 Mixture of pseudoephedrine and 2-(4-(diphenylmethyl)-1-piperazinyl)acetic acid
09/06/2001US20010020022 2{3-[4-(2-t-butyl-6-trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarate
09/06/2001US20010020021 Metalloprotease inhibitor
09/06/2001US20010020020 Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols
09/06/2001US20010020018 Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
09/06/2001US20010020016 Formulation
09/06/2001US20010020015 Combination progestin oral contraceptive regimen
09/06/2001US20010020014 Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
09/06/2001US20010020013 Polymerase inhibitors
09/06/2001US20010020012 Administering ligands for growth horomne receptors
09/06/2001US20010020009 Using plant extract
09/06/2001US20010020008 Administering tagatose
09/06/2001US20010020002 Androgen activity antagonists as therapies for anorexia, anorexia nervosa and disorders characterized by a pathologically underweight condition
09/06/2001US20010019725 High speed mixing of drug and carrier
09/06/2001US20010019724 Carotenoid formulations, comprising a mixture of beta-carotene, lycopene and lutein
09/06/2001US20010019722 Multilayer; sustained release
09/06/2001US20010019719 Intravesical drug delivery system
09/06/2001US20010019717 Moisture retaining component and sesquiterpene alcohol for improving dry or sensitive skin
09/06/2001US20010019716 Ability to enter mammalian cells and to survive within macrophages; vaccines to prevent infection by Mycobacterium tuberculosis, diagnostic assays
09/06/2001DE10035735A1 Composition preventing hair loss contains a combination of biotin or caffeine as effective ingredient together with a 10-18C fatty acid or salt
09/06/2001DE10010430A1 Medicaments, especially for treating anemia, containing 6-(4-(acylamino)-phenyl)-5-ethyl-dihydropyridazinones having erythropoietin sensitizing and erythropoiesis stimulating activity
09/06/2001DE10010426A1 Medicaments, especially for treating anemia, containing 6-(4-(acylamino)-phenyl)-dihydropyridazinones having erythropoietin sensitizing and erythropoiesis stimulating activity
09/06/2001DE10010067A1 New 2-phenyl-imidazo (5,1-f) (1,2,4) triazin-4-one derivatives, are phosphodiesterase inhibitors useful for treating cardiovascular, cerebrovascular or urogenital disorders
09/06/2001DE10009423A1 Cosmetic or pharmaceutical preparation especially for treatment of cellulite comprises nerve fibre stimulator or depolariser, phosphodiesterase inhibitor and antiestrogen
09/06/2001DE10008522A1 Verwendung von 2-PHenylendiaminderivaten zur Behandlung von Infektionen Use of 2-phenylenediamine for the treatment of infections
09/06/2001DE10008159A1 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure (2-MTDC) und /oder ihrer physiologisch verträglichen Salze zur Behandlung und/oder Prophylaxe von Krebserkrankungen Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTCD) and / or their physiologically tolerable salts for the treatment and / or prophylaxis of cancer
09/06/2001DE10006889A1 Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen Use of inhibitors of caspase-3 or caspase-activated deoxyribonuclease (CAD) for the treatment of heart disease
09/06/2001CA2339051A1 Ketolide antibiotics
09/05/2001EP1130122A2 Methods for the diagnosis of polymorphisms in the human EP1-R gene
09/05/2001EP1130103A2 Nucleic acid from Tetrahymena coding for a trieterpenoid-cyclase, its production and use
09/05/2001EP1130020A1 Tropane-derivatives, their preparation and use
09/05/2001EP1130019A1 2,4-bis((4-Amidino)phenyl)furans as anti-pneumocystis carinii agents
09/05/2001EP1130017A2 Azole derivatives and their use as superoxide radical inhibitors
09/05/2001EP1130016A1 Thiocarbamic acid derivatives
09/05/2001EP1129714A1 Use of tiludronic acid and its derivatives in poultry for the preparation of a medicine for preventing and treating osteoporosis
09/05/2001EP1129713A1 Veterinary compositions for the treatment of parasitic diseases
09/05/2001EP1129712A1 Quinolinone derivative preparations and process for producing the same
09/05/2001EP1129711A2 Pinolenic acid against diabetes
09/05/2001EP1129710A2 Method for treating migraine symptoms with ibuprofen and salts thereof
09/05/2001EP1129709A2 Pharmaceutical composition based on ibuprofen and a procedure for the preparation thereof
09/05/2001EP1129708A1 Use of sertraline to treat social phobia
09/05/2001EP1129707A2 Methods for identifying and treating resistant tumors
09/05/2001EP1129706A2 Use of cGMP PDE5 inhibitors for the treatment of neuropathy
09/05/2001EP1129705A1 Powder formulation for inhalation
09/05/2001EP1129699A1 Topical compositions containing whey protein
09/05/2001EP1129697A1 Composition, particularly for cosmetics comprising a pentacyclic triterpene acid
09/05/2001EP1129695A1 Cosmetic or dermatological sunscreen formulations
09/05/2001EP1129694A1 Use of components for modifying physico-chemical properties of the skin and/or the mucosal tissue as adhesion prevention/decreasing adhesion agents for microorganisms
09/05/2001EP1129693A2 Composition for inhibiting body odor and uses thereof
09/05/2001EP1129683A1 Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same
09/05/2001EP1129350A1 Methods for identifying modulators of bs69 activity
09/05/2001EP1129217A2 Compositions and methods of disease diagnosis and therapy
09/05/2001EP1129212A1 Screening process for antibacterial agents
09/05/2001EP1129208A1 Vancoresmycin, a process for its production and its use as a pharmaceutical
09/05/2001EP1129199A2 Cell signaling polypeptides and nucleic acids
09/05/2001EP1129183A2 Human glycine transporter type 2
09/05/2001EP1129177A1 Avipox vector coding an hiv antigen and a cytokine
09/05/2001EP1129112A2 Peptides containing a cholesterol recognition sequence and their uses
09/05/2001EP1129110A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof
09/05/2001EP1129097A1 Novel type condensed pyridazinone compounds
09/05/2001EP1129096A2 Crf receptor antagonists and methods relating thereto
09/05/2001EP1129094A2 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
09/05/2001EP1129093A1 Pyrazolopyrimidinone derivatives for the treatment of impotence
09/05/2001EP1129091A2 Crf receptor antagonists and methods relating thereto
09/05/2001EP1129090A1 PENTAAZA-CYCLOPENTA A]NAPHTHALENE DERIVATIVES AS LIGANDS FOR GABA A? $g(a)5 RECEPTORS
09/05/2001EP1129089A1 Spiro-indolines as y5 receptor antagonists